Seroatlas · Human Serome Atlas

NAT1

Arylamine N-acetyltransferase 1

Also known as: AAC1, ARY1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P18440
Gene: NAT1
Ensembl: ENSG00000171428
Chromosome: 8
Canonical length: 290 aa
Protein class: Enzymes, Metabolic proteins, Predicted intracellular proteins

OverviewNCBI Gene

This gene is one of two arylamine N-acetyltransferase (NAT) genes in the human genome, and is orthologous to the mouse and rat Nat2 genes. The enzyme encoded by this gene catalyzes the transfer of an acetyl group from acetyl-CoA to various arylamine and hydrazine substrates. This enzyme helps metabolize drugs and other xenobiotics, and functions in folate catabolism. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2011]

Canonical amino-acid sequenceUniProt

290 residues, UniProt reviewed canonical sequence.

>P18440|NAT1
     1  MDIEAYLERI GYKKSRNKLD LETLTDILQH QIRAVPFENL NIHCGDAMDL GLEAIFDQVV
    61  RRNRGGWCLQ VNHLLYWALT TIGFETTMLG GYVYSTPAKK YSTGMIHLLL QVTIDGRNYI
   121  VDAGFGRSYQ MWQPLELISG KDQPQVPCVF RLTEENGFWY LDQIRREQYI PNEEFLHSDL
   181  LEDSKYRKIY SFTLKPRTIE DFESMNTYLQ TSPSSVFTSK SFCSLQTPDG VHCLVGFTLT
   241  HRRFNYKDNT DLIEFKTLSE EEIEKVLKNI FNISLQRKLV PKHGDRFFTI

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against NAT1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.22
Highest tissue expression: 14 nTPM

Expression across tissuesHPA

Tissue

epididymis: 14 nTPM
colon: 13 nTPM
rectum: 12 nTPM
duodenum: 11 nTPM
liver: 9.8 nTPM
small intestine: 8.4 nTPM

Single-cell type

respiratory ciliated cells: 176 nCPM
hepatocytes: 48 nCPM
proximal tubule cells: 35 nCPM
colonocytes: 30 nCPM
enterocytes: 28 nCPM
epididymal principal cells: 27 nCPM

Immune cell

eosinophil: 9.4 nTPM
neutrophil: 8.2 nTPM
NK-cell: 6.4 nTPM
T-reg: 6.3 nTPM
myeloid DC: 6.1 nTPM
non-classical monocyte: 5.5 nTPM

Brain region

medulla oblongata: 1.9 nTPM
white matter: 1.4 nTPM
thalamus: 1.1 nTPM
choroid plexus: 1 nTPM
pons: 1 nTPM
cerebellum: 0.9 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.89
gnomAD pLI: 0
gnomAD missense Z: -0.5
DepMap mean gene effect: 0.03
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads NAT1 as an antibody target. Whether an autoantibody or antibody against NAT1 could matter depends on whether native NAT1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

NAT1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label NAT1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...